Compare Abeona Therapeutics Inc (ABEO) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hut 8 Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Hut 8 Corp trades at $91.05 (market cap $10.94B). The key difference: Hut 8 Corp is far larger — about 26× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | HUT | |
|---|---|---|
Market Cap | $421.19M | $10.94B |
Sector | Health | Technology |
52-Week High | $7.45 | $133.02 |
52-Week Low | $4.17 | $21.37 |
Enterprise Value | $276.10M | $18.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
HUT trades at $93.91, up 9.63% today amid a broader neocloud stock rally. The stock shows bearish technical signals with support at $87 and resistance at $92. Fundamentally, revenue grew 81% year-over-year in Q2 2026 to $74 million, but net losses persist with a -188.59% margin. The company is transitioning to an AI data center focus, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (93.75%) and a $165.11 price target reflect optimism in AI infrastructure growth, but high valuation ratios and persistent losses pose risks. Execution on Beacon Point commercialization and debt management are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
